SOUTH SAN FRANCISCO, Calif., May 03, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a
clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor
metabolism and tumor immunology targets for the treatment of cancer, today announced that the Company’s first quarter 2017
financial results will be released on Tuesday, May 9, 2017. Company management will host a conference call on Tuesday, May 9,
2017 at 1:30 p.m. Pacific Time/ 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
The press release and live audio webcast can be accessed via the Investor section of the Company’s website at www.calithera.com. The conference call can be accessed by dialing (855) 783-2599 (domestic) or
(631) 485-4877 (international) and refer to conference ID 18046993. Please log in approximately 5-10 minutes before the
event to ensure a timely connection. The archived webcast will remain available for replay on Calithera’s website for 30
days.
About Calithera Biosciences
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small
molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera’s lead
product candidate, CB-839, is a potent, selective, reversible and orally bioavailable inhibitor of glutaminase. CB-839 takes
advantage of the pronounced dependency many cancers have on the nutrient glutamine for growth and survival. It is currently being
evaluated in Phase 1/2 clinical trials in combination with standard of care agents. CB-1158 is a first-in-class
immuno-oncology metabolic checkpoint inhibitor targeting arginase, a critical immunosuppressive enzyme responsible for T-cell
suppression by myeloid-derived suppressor cells. Arginase depletes arginine, a nutrient that is critical for the activation,
growth and survival of the body’s cancer-fighting immune cells, known as cytotoxic T-cells. CB-1158 is being developed in
collaboration with Incyte Corporation and is currently in a Phase 1 clinical trial. Calithera is headquartered in South San
Francisco, California. For more information about Calithera, please visit www.calithera.com.
CONTACT: Jennifer McNealey ir@Calithera.com 650-870-1071
